Citadel Advisors
ASLN

Citadel Advisors’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Citadel Advisors’s Portfolio ASLN Stock Details ASLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,709
Closed -$35.3K – 15685
2024
Q2 		$35.3K Buy
14,709
+2,633
+22% +$9.33K ﹤0.01% 12112
2024
Q1 		$59.4K Sell
12,076
-48,294
-80% -$242K ﹤0.01% 12006
2023
Q4 		$252K Buy
60,370
+38,810
+180% +$293K ﹤0.01% 9505
2023
Q3 		$319K Buy
21,560
+2
+0% +$37 ﹤0.01% 9053
2023
Q2 		$629K Sell
21,558
-46,090
-68% -$1.43M ﹤0.01% 7433
2023
Q1 		$1.57M Buy
67,648
+185
+0.3% +$5K ﹤0.01% 5830
2022
Q4 		$971K Buy
67,463
+835
+1% +$16.1K ﹤0.01% 6871
2022
Q3 		$1.6M Hold
66,628
– – ﹤0.01% 6027
2022
Q2 		$1.33M Sell
66,628
-895
-1% -$19.9K ﹤0.01% 6390
2022
Q1 		$2.39M Sell
67,523
-425
-0.6% -$15.8K ﹤0.01% 5708
2021
Q4 		$3.04M Sell
67,948
-777
-1% -$46.6K ﹤0.01% 5305
2021
Q3 		$4.89M Sell
68,725
-3,732
-5% -$425K ﹤0.01% 4341
2021
Q2 		$9.56M Buy
72,457
+56,144
+344% +$7.02M ﹤0.01% 3156
2021
Q1 		$2.19M Buy
16,313
+15,414
+1,715% +$1.95M ﹤0.01% 6186
2020
Q4 		$66K Buy
+899
New +$66K ﹤0.01% 10454

Other funds holding ASLN

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citadel Advisors's ASLN Position: Q3 2024 in Review

Citadel Advisors sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2024, closing a stake of 14,709 shares — an estimated $35.3K sold.

Citadel Advisors first reported a position in ASLN in Q4 2020 and held it in 15 quarters. The position peaked at $9.56M in Q2 2021. 1 fund tracked by Wall St. Rank holds ASLN as of Q3 2024.

  • Citadel Advisors reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 14,709 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2024, an estimated $35.3K.
  • Citadel Advisors first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2020 and held it in 15 quarters.
  • Citadel Advisors's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $9.56M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.